News

‘Spotify Shutters In-House Podcast Studio, Lays Off Staff’ -Variety Report

https://variety.com/2022/digital/news/spotify-studios-shut-down-layoffs-1235151124/

byBenzinga Newsdesk

January 11, 2022

1 minute read

https://variety.com/2022/digital/news/spotify-studios-shut-down-layoffs-1235151124/

Citigroup Maintains Buy on Apple, Lowers Price Target to $175

By Benzinga Newsdesk

July 13, 6:43 AM

Citigroup analyst Jim Suva maintains Apple (NASDAQ:AAPL) with a Buy and lowers the price target from $200 to $175.

AAPL

B of A Securities Maintains Buy on Catalent, Lowers Price Target to $125

By Benzinga Newsdesk

August 30, 7:11 AM

B of A Securities analyst Derik De Bruin maintains Catalent (NYSE:CTLT) with a Buy and lowers the price target from $140 to $125.

CTLT

Horizon Therapeutics Reports Results From New Analysis Of UPLIZNA Phase 2/3 Trial Showing A Correlation Between Depth Of B-Cell Depletion, Improved Neuromyelitis Optica Spectrum Disorder Patient Outcomes

By Benzinga Newsdesk

October 13, 8:13 AM

-- Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced results from a new analysis of the

HZNP

Discovery Q4 Adj. EPS $(0.37) Misses $(0.20) Estimate, Sales $11.01B Miss $11.36B Estimate

By Michael Horton

February 23, 5:05 PM

Discovery (NASDAQ: WBD) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.20) by 85 percent. This is a 562.5 percent decrease over earnings of $0.08 per share from the same period last year.

WBD

‘Spotify Shutters In-House Podcast Studio, Lays Off Staff’ -Variety Report

Related Posts

Citigroup Maintains Buy on Apple, Lowers Price Target to $175

B of A Securities Maintains Buy on Catalent, Lowers Price Target to $125

Horizon Therapeutics Reports Results From New Analysis Of UPLIZNA Phase 2/3 Trial Showing A Correlation Between Depth Of B-Cell Depletion, Improved Neuromyelitis Optica Spectrum Disorder Patient Outcomes

Discovery Q4 Adj. EPS $(0.37) Misses $(0.20) Estimate, Sales $11.01B Miss $11.36B Estimate